- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02106611
Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors
December 27, 2023 updated by: Memorial Sloan Kettering Cancer Center
This study will test whether cardiac MRI can improve early detection of Hodgkin lymphoma associated heart disease compared to a stress echocardiogram.
By doing both stress echocardiography and cardiac MRI, we will compare the ability of the two tests to detect heart disease.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
133
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
MSKCC
Description
Inclusion Criteria:
- Classical or nodular lymphocyte predominant HL treated at Memorial Sloan-Kettering Cancer Center.
- Age ≥ 18 years
- Treatment for HL that included mediastinal RT at initial diagnosis or relapse.
- ≥ 5 years from last HL treatment.
Exclusion Criteria:
- Primary HL diagnosis prior to 1980.
- Additional mediastinal RT or subsequent cardiotoxic systemic therapy for secondary malignant neoplasm.
- Known CAD/CHF (defined as documented myocardial infarction, cardiac revascularization, angiographic obstructive CAD, or decreased LV function [EF < 55%] during prior clinical care).
- Contraindication to MRI (i.e. pacemakers, defibrillators, or aneurysm clips, or other implanted ferromagnetic objects), gadolinium (i.e. known hypersensitivity to gadolinium, advanced renal insufficiency as defined by glomerular filtration rate <30 ml/min/1.73m^2).
- Contraindication to exercise stress testing other than the above (i.e. unstable angina or severe valvular stenosis).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hodgkin Lymphoma Survivor
This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
|
HL treatment will be determined by review of available medical records as archived at MSKCC.
Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages.
Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
compare the prevalence of cardiac injury
Time Frame: 2 years
|
detected by cardiac MRI to that detected by stress echocardiography among a broadly representative cohort of Hodgkin lymphoma survivors.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2014
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
April 1, 2025
Study Registration Dates
First Submitted
April 3, 2014
First Submitted That Met QC Criteria
April 3, 2014
First Posted (Estimated)
April 8, 2014
Study Record Updates
Last Update Posted (Actual)
December 28, 2023
Last Update Submitted That Met QC Criteria
December 27, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hodgkin Lymphoma Survivor
-
National Cancer Institute (NCI)CompletedRecurrent Adult Hodgkin Lymphoma | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Adult Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma | Adult Favorable Prognosis... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedStage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingClassic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage IA Hodgkin LymphomaUnited States
-
Northwestern UniversitySeagen Inc.; Robert H. Lurie Cancer CenterUnknownStage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Childhood Hodgkin LymphomaUnited States, Canada, Puerto Rico
-
National Cancer Institute (NCI)The Lymphoma Academic Research OrganisationActive, not recruitingHIV Infection | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin... and other conditionsUnited States, France
Clinical Trials on Clinical Assessment
-
Thomas Jefferson UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Florida International UniversityNational Institute of Mental Health (NIMH); University of MiamiCompletedDisruptive BehaviorUnited States
-
Fondazione Don Carlo Gnocchi OnlusCompletedChronic Low-back PainItaly
-
Czech Technical University in PragueMayo Clinic; University Hospital, Montpellier; McGill University Health Centre... and other collaboratorsUnknownParkinson Disease | REM Sleep Behavior DisorderUnited States, Canada, Austria, Czechia, France, Germany, Italy
-
Halic UniversityCompletedTemporomandibular Joint Dysfunction SyndromeTurkey
-
Assiut UniversityNot yet recruitingFeeding; Difficult, Newborn | Pre-Term
-
NHS Greater Glasgow and ClydeBiogenEnrolling by invitationRelapsing Remitting Multiple SclerosisUnited Kingdom
-
University Hospital, MontpellierUnknown
-
KU LeuvenUniversitaire Ziekenhuizen KU LeuvenRecruiting